GOBIOM
  • About us
  • Publications
  • News
  • Events
  • Faqs
  • Contact
  • Feedback
  • covid-19
  • Customer Login
  • Biomarker Database for Informed Clinical & Therapeutic Decision Making

    Choose the best biomarker to diagnose disease, monitor disease progression, treatment selection, predicting treatment outcome, monitoring treatment efficacy and safety
    View Demo Get Your Licence
  • Relational Data Model Connecting Biomarker to Disease & Drug

    Unique tetrahedron data model connecting biomarker to disease and drug to simplify the process of biomarker data analysis
    View Demo Get Your Licence
  • Preclinical to Clinical Translation of a Biomarker

    Get access to supporting preclinical data for the evaluated clinical and exploratory clinical biomarkers
    View Demo Get Your Licence
  • Gain Insights on Translational, Emerging and Established Biomarkers

    Accelerate your clinical research with valuable insights into pre-clinical biomarkers, emerging biomarkers and biomarkers evaluated in clinical trials

    View Demo Get Your Licence
  • Diversified Analytics to Derive Meaningful Insights

    Uncover insights hidden in the complex biomarker data using interactive and dynamic analytic and visualization tools
    View Demo Get Your Licence
  • Customized Reports on Biomarkers, Diseases & Drugs

    Biomarker data is presented as intuitive and searchable reports for 360 degree view on biomarker, disease and drug
    View Demo Get Your Licence
  • Approved Diagnostic and Companion Diagnostics

    Get access to approved diagnostic and companion diagnostic kits which are in discovery and development
    View Demo Get Your Licence
Biomarkers
Indications
Utilities
Methodologies
Endpoints
Drugs
New Biomarkers

Last Update:

Understand complex 'biomarker data' with GOBIOM

Heatmap
Visualization

Comparative
Analysis

Search
Results

Chromosomal
view

Intuitive
Reports

Dynamic
Dashboards

Quick
Search

Variant
Analysis

Heatmap Visualization
Comparative Analysis
Search Results
Chromosomal View
Intuitive Reports
Dynamic Dashboard
Quick Search
Variant Analysis

GOBIOM Highlights

Intuitive Biomarker reports
Intuitive Biomarker reports
Reports with integrated filtering options
Reports with integrated filtering options
Heat map Visualization & Clustering
Heat map Visualization & Clustering
Expression Profile
Expression Profile
Search List View with Visualization
Search List View with Visualization
Marker-Marker Correlation
Marker-Marker Correlation
Off-Label Indications
Off-Label Indications
Clinical Guidelines
Clinical Guidelines
Variant Analyser
Variant Analyser
Comparative Analysis
Comparative Analysis
Biomarker Watchlist
Biomarker Watchlist
API services
API services

What's New on GOBIOM

  • Overview
  • Content
  • Features
  • Users & Benefits
The true value of GOBIOM biomarker database is measured by the critical questions that it can address for the success of the clinical trials and accelerating drug development.

Are there any diagnostic biomarkers?

Are there any biomarkers to identify disease progression and prognosis?

What are the markers linked to efficacy/toxicity of a drug?

Are there any biomarkers approved by regulatory authorities?

Are there any evidence based clinical practice guidelines issued by professional societies?

Is the biomarker translating from preclinical to clinical models?

What are the clinical endpoints to which a biomarker is significantly correlated?

What is the study population who would be most benefitted by a therapy?

How many clinical trials are associated with a given biomarker? What is the biomarker outcome in each trial?

What are the approved diagnostics and companion diagnostics for a given biomarker and who are the assay vendors?

What are the drug resistance biomarkers reported for a given therapy?

Are there any off-label uses of the approved drugs?

BIOMARKER UTILITIES

Each biomarker is assigned with the following utilities as reported by the investigator

Diagnosis:

Biomarkers which indicate the presence or likelihood of a particular disease in patients or in animal models.
Ex: Significantly elevated serum carbonic anhydrase 1 (CA1) level is reported as a novel early diagnostic biomarker in stage I non-small cell lung cancer (NSCLC) patients compared to healthy control subjects

Prognosis:

Biomarkers which can discriminate between patients at high and low risk of a clinical outcome.
Ex: Estrogen receptor, beta in Breast cancer
High epithelial Lysosomal-associated membrane protein 3 (LAMP3) expression is reported as a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma

Progression of disease:

Biomarkers which can indicate the progression of disease.
Ex: Dysregulation of glutathione S-transferase pi 1 (GSTP1) is reported as novel biomarker predicting aggressive disease and disease progression in African American men with prostate cancer

Efficacy:

Biomarkers which correlate with the desired effect of a treatment.
Ex: FEV1 is reported as a efficacy biomarker as evident by its significant improvement following treatment with MK-7123 in chronic obstructive pulmonary disease patients

Response to therapy:

Biomarkers predictive of response to a treatment.
Ex: Whole blood alpha defensin DEFA1 mRNA expression is reported as a predictive biomarker of drug response in castration-resistant prostate cancer (CRPC) patients receiving docetaxel treatment

Surrogate:

Markers which substitute a desired clinical outcome and which can be measured months or even years before meaningful clinical endpoints like mortality or morbidity.
Ex: Increased BNP is correlated with the extent of myocardial ischemia, age, renal insufficiency, and ventricular dysfunction in patients with acute coronary syndrome suggesting that BNP may be useful as a surrogate marker for multiple conventional risk factors.

Safety:

Indicate potentially harmful effects of a drug in clinical population
Ex: Blood alkaline phosphatase is reported as a safety biomarker as evidenced by its increased level in 1.27% gastric cancer patients treated with ramucirumab as compared to 0% patients treated with placebo

Toxicity:

Indicate potentially harmful effects of a drug in cell-based or preclinical studies.
Ex: Gentamicin sulfate induced nephrotoxicity was measured in terms of significantly increased renal, urinary and serum clusterin levels respectively in adult Lewis rats after 12 days of treatment at 100 mg/kg/day

Pharmacokinetic:

Biomarkers which can be used to indicate the pharmacokinetic properties of the drug
Ex: Ferritin is reported as a pharmacokinetic biomarker as evident by significant association between serum ferritin level and volume of drug distribution of non-conjugated deferiprone and urinary iron excretion in splenectomized and non-splenectomized Beta-Thalassaemia/haemoglobin E patients treated with a single oral dose of deferiprone at a dose of 25 mg/kg

Biomarker Classification & Utilities

Biomarkers are classified based on the biomarker status (pre-clinical, exploratory & clinical), nature and technique used to measure a biomarker or by the chemical nature of the biomarker. Diverse utilities of biomarkers representing the utility of the biomarker from the author's perspective in the curated reference.

Biomarker Qualification

Evidence based FDA/EMEA/PMDA approved biomarker qualification information associating biomarker to specific biological process or clinical end point

Biomarker Experimental Details

Biomarker specific information including biological specimens evaluated, experimental technique used, FDA/EMEA/PMDA approved diagnostic kits, approved companion diagnostics, assay provider information and assay analytical qualification details

Clinical Trials

Information on clinical trial design, biomarkers evaluated, clinical endpoints, sponsors and collaborators, phase of the study, study population, ethnicity details etc.

Drugs/Intervention

Information on drugs/interventions, drug target pathways, drug targets, end points, efficacy and safety characteristics, off-label drug uses, drug induced toxicity and drug resistance

Preclinical Biomarkers

Preclinical information of putative biomarkers of human diseases in animal models and cellular models

Manual Curation of Biomarker Data

Manual curation of each data field ensuring accuracy of data

Controlled Vocabulary

Standard nomenclature/ontology throughout the database to ensure consistency and effective information retrieval

Unbiased Biomarker Utility Reporting

Biomarker utility i.e. both supporting and contradicting represented in an unbiased manner

Biomarker Watchlist

Receive notifications for biomarkers in the watchlist whenever biomarker data has been updated

Off-Label Drug Uses

Get insights on unapproved usage of approved drugs with published evidence

Analytics & Visualization

Analyze and visualize complex biomarker datasets using our advanced visualization tools

Periodic Database Updates

Biweekly database updates with auto alert function for all users

Flexible Download Options

Download customized biomarker data as reports and in pre-designated formats like Excel, XML or PDF for in-house analysis

Custom alerts and on-demand curation services

Get custom alerts by therapeutic area and biomarker name of interest by subscribing to the custom alert service. Avail our on-demand curation services for customized updation or addition of biomarkers of interest in the database.

USERS

System Biologists

Clinical and Preclinical Scientists

Translational Researchers

Clinical Development Teams

Pharmacology & Toxicology Teams

Diagnostics Development Teams

BENEFITS

Competitive Intelligence

GOBIOM provides critical information on ongoing and completed clinical trials in addition to companies involved in drug discovery and development. It also provides insights into the competitive landscape in a given therapeutic area or a specific indication

Target Discovery/Identification

GOBIOM enables discovery biologists working on an indication to gain insights into proteins/genes targeted by drugs. Genes/proteins activated in the disease condition i.e. diagnostic biomarkers can serve as a therapeutic target enabling discovery of new drugs.

Drug Repositioning

GOBIOM can help companies involved in new drugs development to gain insights into probable use of the drug in other indications. Analysis of Top 10 indications vis-a-vis number of biomarkers can provide insights into drug repositioning in indications other than which the drug is intended to use.

Clinical Decision Support

GOBIOM can help identify/stratify patients who will respond to the treatment and also identify efficacy biomarkers which aids in designing effective clinical trials

Clinical Trial Insights

GOBIOM provides insights into clinical trial landscape vis-a-vis ethnicity, sample size and different specimens evaluated for measuring the biomarker. It also provides information about evaluated end points in different studies which could assist researchers in incorporating the most relevant endpoints in the clinical trials

Safety/Toxicity Profiling

GOBIOM enables safety/toxicity profiling of a drug by assessing the biomarkers reported for toxicity and safety application. Researchers working on a compound can gain insights into the biomarkers of toxicity, response and resistance

Contact Us

World Map

India Office

EXCELRA
6th Floor, Wing B, NSL SEZ ARENA,
Plot No. 6, Survey No. 1, IDA Uppal,
Hyderabad-500039, India.
biomarkers@excelra.com
+91 40 6707 3333

USA (Boston) Office

Excelra Inc
200 Portland St
Boston, MA 02114
USA
biomarkers@excelra.com

JAPAN Office

ITOCHU Techno-Solutions Corporation (Distributor) ART Village Osaki Central Tower, 1-2-2,
Osaki, Shinagawa-ku,
Tokyo 141-8522
biomarkers@excelra.com
+81-3-6203-5000

Enquiry Form

*
*
*
Submitted successfully!
Error! in sending mail.

About Us

GOBIOM BIOMARKER DATABASE: GOBIOM Biomarker Database is a comprehensive biomarker database that provides information on Proteomic, Genomic, Biochemical, Imaging, Metabolite, Clinical Scoring scales and Cellular biomarkers for 18 different therapeutic areas, covering ~3000 therapeutic indications with its reported utilities like diagnosis, prognosis, monitoring disease progression, treatment response, surrogate, efficacy and toxicity. Information in GOBIOM biomarker database is gathered from diverse sources which include clinical trials, scientific conferences, regulatory-approved documents, literature databases etc.

A proprietary Tetrahedron model is adopted in the framework of the database to simplify the process of biomarker data analysis.

a team of

650+

scientists with rich experience in Chemistry, Biology and Clinical Sciences
GOBIOM Info

Excelra Road map

Our Biology services spans across custom curation, Bio-IT and Data Analytics providing solutions for targeted literature curation, vocabulary management, data mining, database development & integration, data harmonization, & Visualization. Our curation services reduce the time and costs required towards drug development R&D and achieve better outcomes. Outcomes successfully delivered include actionable mutations for targeted therapy, Clinical genome variant interpretation & reporting, Gene set enrichment analysis & pathway analysis, Text mining & analysis of clinical trial data, Gene annotation & ontology mapping, Phenotype reporting & outcome mapping, Biological process annotation of proteins, Multiomics data integration & analysis, and Off-label use of approved drugs.

Publications

Top Citations

Italian TrulliImmunotherapy biomarkers 2016: overcoming the barriers

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH

Italian TrulliAnalysis of cancer-specific isoforms across the cancer genome atlas tumor types: potential disease linkages

Yan Ji, Yunqin Chen, Ming Chen, Jia Wei R & D information China, AstraZeneca, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai, 201203, China

Italian Trulli"Nuts and Bolts" of Laboratory Evaluation of Angioedema

Farkas H, Veszeli N, Kajdácsi E, Cervenak L, Varga L.

Italian TrulliAnalysis and Classification of Transcription Data for the Detection of Potential Biomarkers in Cancer

Mr. Yantao Gao

Italian TrulliUsing bioanalysis for cancer diagnosis and prognosis

Markuszewski MJ, Kaliszan R.

Italian TrulliGenomic Biomarkers for Pharmaceutical Development: Chapter 2. Personalized Health Care (PHC) in Cancer

Yihong Yao, Bahija Jallal and Koustubh Ranade

Italian TrulliBiomRKRS: a biomarker retrieval and knowledge reasoning system

Ofoghi, Bahadorreza, Lopez Campos, GH, Vrespoor, K and Martin Sanchez, FJ 2014, BiomRKRS: a biomarker retrieval and knowledge reasoning system, in HIKM 2014:Proceedings of the Seventh Australasian Workshop on Health Informatics and Knowledge Management, Australian Computer Society, Sydney

Italian TrulliChallenges and opportunities for oncology biomarker discovery

Deyati A, Younesi E, Hofmann-Apitius M, Novac N Merck Serono

Italian TrulliCombining imaging and pathway profiling: an alternative approach to cancer drug discovery

Carragher NO1, Brunton VG, Frame MC.

Italian Trulli13,000-biomarker deal

Killugudi Jayaraman Indiana CTSI

Italian TrulliDifferentially Expressed RNA from Public Microarray Data Identifies Serum Protein Biomarkers for Cross-Organ Transplant Rejection and Other Conditions

Chen R, Sigdel TK, Li L, Kambham N, Dudley JT, Hsieh SC, Klassen RB, Chen A, Caohuu T, Morgan AA, Valantine HA, Khush KK, Sarwal MM, Butte AJ.

Italian TrulliMethods for monitoring allograft rejection

BUTTE, Atul, J, CHEN, Rong The Board Of Trustees Of The Leland Stanford Junior University

Italian TrulliThe Handbook of Biomarkers

Jain, Kewal K.

Italian TrulliIdentifying good efficacy, safety and drug response biomarkers in Rheumatoid Arthritis

Nikhil T, Jesintha M, Vijaya Rao P, Arul P, Madhukar P

Italian TrulliInterpretation of Common diagnostic markers reported for Colorectal Cancer and other indications for the development of multiplex biomarker panels; Analysis using GOBIOM Biomarker Database

Madhukar P, Nikhil T, Vijaya Rao P, Pavan B, Srikanth Y, Suman CH, Ramadevi S

Italian TrulliAnalysis of predictive biomarkers reported for NSCLC treatment

Vijaya Rao P, Madhukar P, Pavan B, Yasmeen S, Govardhan K, Sreeni Devidas, Ramadevi S

Italian TrulliDrug-induced nephrotoxicity analysis in HIV therapy; Case study using creatinine biomarker data from GOBIOM database

Madhukar Reddy Patlolla, Vijaya Rao Pidugu, Pavan Kumar Bhatta, Sreenivasa Rao Guggilla, Rama Devi Sanam, Sreeni Devidas

Italian TrulliHeat map visualization of the diagnostic biomarkers that overlap between Pancreatic cancer and other indications; Analysis using GOBIOM data

Sreeni Devidas, Ramadevi Sanam, Sreenivasa Rao Guggilla, Vijaya Rao Pidugu, Pavan Kumar Bhatta, Madhukar Reddy Patlolla, Srikanth Yinala, Rajkumar Kommalapati, Suman Challa, Ayyappa Chaturvedula

Italian TrulliClinical Utility of Circulating Tumor Cells Enumeration in Breast Cancer Prognosis

Sreeni Devidas, Ramadevi Sanam, Sreenivasa Rao Guggilla, Vijaya Rao Pidugu, Pavan Kumar Bhatta, Madhukar Reddy Patlolla

Italian TrulliOsteopontin as a Diagnostic biomarker in cancer research - Analysis using GOBIOM database

Sreeni Devidas, Ramadevi Sanam, Sreenivasa Rao Guggilla, Vijaya Rao Pidugu, Sarma Jagarlapudi

Italian TrulliBIOMARKERS IN CLINICAL DRUG DEVELOPMENT

Sreeni Devidas, Ramadevi Sanam, Sunita Tajne, Sarma Jagarlapudi

Case Studies

Identifying potential drug targets for Alzheimer's disease
view pdf
Identification of efficacy, response to therapy and drug resistance biomarkers in breast cancer
view pdf
Identification of safety biomarkers evaluated against AMPK inhibitors
view pdf
Identification of panel of diagnostic biomarkers evaluated in Bile duct cancer
view pdf
Identification of alternate uses for Aspirin in new indications
view pdf

News & Events

Current Events

June

World Pharma Week

18-20th June, Boston, USA

Sept

Precision Medicine and Biomarker Leaders

Sept 2019, Germany, Europe

Oct

ASHG (American Society of Human Genetics) 2019 Annual Meeting

15-19 October 2019, Houston, USA

Past Events

Sept

The 5th Global Precision Medicine & Biomarkers Leaders Summit

Sep 17 - 18, 2018, Munich, Germany

Sept

Annual Biomarkers Congress

Sep 20 - 21, 2018, Osaka, Japan

News & Press Releases

Apr
08
2019
Hyderabad India

Excelra launches GOBIOM+, an intuitive avatar of its flagship biomarker intelligence platform

Excelra (www.excelra.com), a leading data and analytics company, announced the successful release of GOBIOM+ (Global Online Biomarker Database), the most comprehensive and high-quality biomarker intelligence platform. GOBIOM+ is geared to support quick, reliable and data-driven decision making in translational drug development.

Nov
21
2016
Mountain View California

Excelra Earns Acclaim from Frost & Sullivan for its GOBIOM Database, the World's Largest Repository of Clinical, Pre-Clinical, and Exploratory Biomarkers

The GOBIOM platform's content for biomarker assay techniques can alleviate the risks associated with biomarker-based clinical trials

Feb
04
2013
Hyderabad India

US FDA Extends License of the GVK BIO Biomarker database

GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (USFDA). The GOBIOM database, which has the latest and recently updated information on all the biomarkers reported in various clinical and preclinical studies, will be beneficial to the USFDA in its Biomarker Qualification Process.

Readmore

US FDA Extends License of the GVK BIO Biomarker database

×
February 04th, 2013; Hyderabad, India: GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (USFDA). The GOBIOM database, which has the latest and recently updated information on all the biomarkers reported in various clinical and preclinical studies, will be beneficial to the USFDA in its Biomarker Qualification Process. The GOBIOM database is a comprehensive compilation of all the clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. GOBIOM contains information on 20,000 biomarkers comprising of biochemical, genomic, imaging, metabolite, cellular and physiological markers, along with multiple data points comprising of experimental, analytical, clinical and statistical data with their qualifications under different medical interventions. SreeniDevidas, Vice President, Sales & Marketing, Informatics said the collaboration with The USFDA has helped GVK BIO in developing the safety biomarker content in GOBIOM. The interconnectivity between organ toxicities to the drug, dose and population was developed with equal emphasis on its preclinical qualification. Biomarker analysis tools were integrated into the database in a manner that has facilitated the user to make a comparative analysis between the biomarkers of their interest. We look forward to continue working and collaborating with the FDA with a view to enhancing the utility of the product further.
Sep
04
2012
Hyderabad India

GVK Biosciences licenses its Biomarker Database to The Division of Cancer Prevention, National Cancer Institute

GVK Biosciences (GVK BIO), Asia's leading contract research organization announced today that it has licensed its popular clinical biomarker database (GOBIOM) to the prestigious Division of Cancer Prevention (DCP), National Cancer Institute (NCI).

Readmore

GVK Biosciences licenses its Biomarker Database to The Division of Cancer Prevention, National Cancer Institute

×
September 4th, 2012; Hyderabad, India: GVK Biosciences (GVK BIO), Asia's leading contract research organization announced today that it has licensed its popular clinical biomarker database (GOBIOM) to the prestigious Division of Cancer Prevention (DCP), National Cancer Institute (NCI). The GOBIOM (GVK BIO Online Biomarker Database) is a comprehensive collection of all clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. GOBIOM contains information on 15,500 biomarkers comprising of Biochemical, Genomic, Imaging, Metabolite, Cellular and Physiological markers with multiple data points covering experimental, analytical, clinical, preclinical and statistical data with their qualifications under different medical interventions. GOBIOM covers over 100 different ethnicities, provides extensive information on approved assay methodologies & companion diagnostics and is a powerful tool for researchers and clinicians worldwide. Biomarker Research is growing exponentially in the area of Oncology. The GVK Database has over 6000 Clinically evaluated markers in oncology and growing. "GVK BIO is pleased that the DCP chose the GVK BIO Biomarker Database for its research efforts. It is a clear testimony to the quality, content and utility of the database. We look forward to working with DCP. The coverage in Oncology will enable researchers at the DCP to accelerate their discovery efforts", said SreeniDevidas, Vice President, Sales & Marketing - Informatics.
June
08
2011
Hyderabad India

Indiana CTSI partners with GVK Biosciences to provide national access to biomarkers database

In an agreement facilitated by the Indiana Economic Development Corporation (IEDC) during a February economic mission to India, the Indiana Clinical and Translational Sciences Institute (CTSI) has partnered with GVK Biosciences, Asia's leading Contract Research Organization, to provide researchers across the United States access to GVK BIO's Clinical Biomarker Database that will advance research on wide range of diseases. The Indiana CTSI Bioinformatics Core and Indiana Institute for Personalized Medicine will work together to manage the process by which researchers access this new resource.

Readmore

Indiana CTSI partners with GVK Biosciences to provide national access to biomarkers database

×
June 08, 2011, Hyderabad: In an agreement facilitated by the Indiana Economic Development Corporation (IEDC) during a February economic mission to India, the Indiana Clinical and Translational Sciences Institute (CTSI) has partnered with GVK Biosciences, Asia's leading Contract Research Organization, to provide researchers across the United States access to GVK BIO's Clinical Biomarker Database that will advance research on wide range of diseases. The Indiana CTSI Bioinformatics Core and Indiana Institute for Personalized Medicine will work together to manage the process by which researchers access this new resource. The GVK Biosciences Clinical Biomarker Database known as (GOBIOM) is a comprehensive collection of all clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. The resource will be available nationwide to 55 medical centers and universities supported by the Clinical and Translational Sciences Award from the National Institutes of Health. "The GOBIOM database is a powerful tool for clinicians and researchers looking to mine the most up to date and comprehensive information about any putative biomarker for personalized therapeutics," said Anantha Shekhar, director of the Indiana CTSI. "The Indiana CTSI is very pleased to partner with GVK BIO and the Indiana Institute for Personalized Medicine to make this resource available to all clinical and translational researchers in the national consortium. I am also grateful to the Indiana Economic Development Corporation for facilitating the GVK BIO and CTSI partnership." "GVK BIO is pleased that the Indiana CTSI chose the GVK BIO Biomarker Database for its research efforts. Biomarker research is increasing at a rapid pace and the database is designed to help researchers keep pace with the latest data. We look forward to collaborating with the CTSI and further improving the product to address the needs of the researchers and reviewers," said SreeniDevidas, Ph.D., vice president for sales and marketing in informatics at GVK Biosciences. "From research and development to commercialization, Indiana's wealth of expertise in life sciences has improved the knowledge and quality of medicine for researchers and patients around the world. The partnership between GVK Biosciences and the Indiana CTSI sprung from initial meetings during our February economic mission to India and has quickly developed into a tangible partnership that could be the precursor for future global opportunities," said Mitch Roob, secretary of commerce and chief executive officer of IEDC. GOBIOM contains information on 12,000 biomarkers comprising biochemical, genomic, imaging, metabolite, cellular and physiological markers with multiple data points covering experimental, analytical, clinical and statistical data with their qualifications under different medical interventions. The GOBIOM database contains the latest and updated information on all the biomarkers reported in various clinical and preclinical studies.
Nov
15
2011
Hyderabad India

GVK Biosciences Partners with the PROOF Centre of Excellence, University of British Columbia in Biomarker Development and Commercialization

GVK Biosciences (GVK BIO), Asia's leading drug discovery research and development organization, announced today a new partnership with the PROOF Centre of Excellence, focusing on biomarker development for heart, lung and kidney failure.

Readmore

GVK Biosciences Partners with the PROOF Centre of Excellence, University of British Columbia in Biomarker Development and Commercialization

×
November 15th, 2011; Hyderabad, India: GVK Biosciences (GVK BIO), Asia's leading drug discovery research and development organization, announced today a new partnership with the PROOF Centre of Excellence, focusing on biomarker development for heart, lung and kidney failure. The PROOF (Prevention of Organ Failure) Centre, a not-for-profit Centre of Excellence for Commercialization and Research funded by the Government of Canada, has licensed the popular GVK BIO Online Clinical Biomarker Database (GOBIOM) to help evaluate the commercialization potential of the PROOF Centre's biomarkers for heart, lung and kidney disease. "Heart, lung and kidney diseases are a tremendous cost to society - in dollars and lives. Our mission at the PROOF Centre is to create new tools that will help alleviate this global burden," says Dr. Bruce McManus, Director of the PROOF Centre. "Integrating knowledge from GVK Biosciences" Biomarker Database will be a significant advantage in helping us accelerate the transfer of these new tests into the clinic-ensuring patients will benefit faster." The GOBIOM database is a comprehensive collection of all the clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. GOBIOM contains information on 14,000 biomarkers comprising of Biochemical, Genomic, Imaging, Metabolite, Cellular and Physiological markers with multiple data points covering experimental, analytical, clinical and statistical data with their qualifications under different medical interventions. Over 100 different ethnicities are covered in the database. The unique data model links the Biomarker to the Drug, Therapeutic Area and Target and allows users to query the database in multiple ways. The database also contains significant amount of Toxicity and Adverse Events data. SreeniDevidas, Vice President, Sales & Marketing - Informatics, said "the GOBIOM database has received good response from the academia and industry. The license by the PROOF Centre of Excellence further validates the utility of the database. We look forward to working with the researchers at the PROOF Centre of Excellence and helping them in their scientific strategies."

FAQ's

What is GOBIOM?

GOBIOM (Global Online Biomarker Database) is an online scientific database product of Excelra Knowledge Solutions Pvt. Ltd. The database is a comprehensive collection of all the clinically evaluated and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials and other scientific literature. GOBIOM has information on Biochemical, Genomic, Proteomic, Imaging and Metabolite markers with 340 data points for each marker covering its clinical as well as preclinical qualification. All data entries are hyperlinked to the Reference.

What is your selection criteria for a biomarker?

We follow biomarker definition by NIH
The official NIH definition of a biomarker is: "a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention." We go through all the clinical trials, published literature and scientific conferences to look at the studies where at least a single biomarker is measured. We developed ontology dictionary for the biomarker keyword, which is used to screen the literature.

What are your Literature sources?

Literature sources includes Clinical trial registries, Clinical trial study result registries, Scientific Conferences, PubMed, Patents, 510K and PMA databases, FDA Approved Documents and Newsletters

What is the source of ontologies, taxonomies?

We follow WHO ICD-10 and NCI for therapeutic class and disease classification. Adverse events data is mapped according to the MedDRA. Gene and Protein nomenclature is adopted according to NCBI gene. In other sections like Specimen and experimental methodology where no standard ontologies are available, we developed our own ontology

Does GOBIOM have controlled vocabulary?

Sophisticated ontology infrastructure and in-house curation tool enable us to organize with controlled vocabulary dictionaries. All data points in GOBIOM are regulated through very stringent QA mechanism

What are the export formats?

GOBIOM UI enables user to export data in MS Excel, XML and PDF formats.

Frequency of updates to web and dump?

For every 15 days GOBIOM online data is updated. Data feed is provided monthly, quarterly or annually according to the client's need.

Do you send custom alerts when the database is updated?

For every data update an automatic email will be sent to users by GOBIOM application. Enhancements in application will be updated to user and a training session will be conducted to train users on new features.

How can a user customize alerts?

User can set-up alerts on specific Therapeutic class, Nature, Biomarker and Disease name. User will receive email whenever data gets updated on those parameters.

Is it possible to provide the data in custom format?

Yes, data will be delivered in the client specified format. GOBIOM data can be customized according to the client need.

Will you help us in integrating GOBIOM with our internal databases?

Yes, GOBIOM team will help in integration of data with internal databases according to customer need. GOBIOM data can be easily integrated because it contains many public identifiers for Protein, Gene, Drug and Disease etc.

Explain your team?

GOBIOM team has world class pool of Ph.D or Masters in Pharmacology or Life sciences with strong knowledge on drug development process and biomarkers. Members are well aware of the Clinical Data sources and search methodology, efficient in searching clinical trials, scientific conferences and literature databases with good text mining skills

Do you screen/curate patents?

We screen all the patents but patents with selective information on a specific biomarker or a panel of biomarkers with experimental data will be selected for curation

How do you identify latest information on biomarkers?

We have a dedicated team who follow news on biomarkers, assay kits, scientific conferences, clinical trials and results. Hence we ensure all the latest information of biomarkers are updated in GOBIOM

Can I evaluate the database before taking a decision?

Sure, you can evaluate GOBIOM with free trial access. To get a trial access you can raise request by clicking on Evaluation request of GOBIOM website or write to biomarkers@excelra.com Along with evaluation access you can also request for demo of GOBIOM which can be arranged at your convenience

What are the external databases to which GOBIOM is connected?

GOBIOM is cross linked with well-known publicly available databases like NCBI PubMed, Gene, KEGG Pathways, PubChem, Clinicaltrial.gov, Scientific conference web sites, Patent database, WHO ICD-10 database, ChemID Plus etc.

Does my browser support GOBIOM application?

For the best experience, we recommend you to use Google Chrome or IE or Firefox or Safari as your browser. Please make sure that JavaScript and style sheets are enabled in the browser. This site is best viewed at a resolution of 1024x768

How to send feedback on the database?

We would love to hear from you. Just click on the feedback link and submit your feedback.

What should I do if I forgot my password?

If you forget your password, click on 'Forgot Password' option in the login page. Enter your email address/user name in the text box provided to receive your new password.

What should I do if I do not receive my 'Forgot Password' email?

Rarely our emails are blocked or they are sent to the spam folder. If you have not received the lost password email, please check the spam/junk email folder. If you don't find the email in spam/junk email folder, you can contact the GOBIOM support team at biomarkers@excelra.com for further assistance

How do I change the password?

You can change your password by clicking the 'My account' link after logging in. Select the 'change password' option to change your password.

Can I change my user name?

It is not possible to change your username once you've signed up for GOBIOM account.

What should I do if I forget my username?

We maintain a record of all the user details. If you no longer have the email sent to you with username and password. You can recover your username by contacting the support team. Your username will be sent to you via email.

I'm having trouble logging in?

Some possible reasons for this are:
  • Logging in with wrong username or password
  • Unsupported browser
  • Cookies
  • If you still can't login, contact the support team at biomarkers@excelra.com

I'm having trouble loading the site?

Loading problems may occur if a setting in your browser, or in third-party software, conflicts with GOBIOM. To solve this problem, first check that you are using a supported browser, then try clearing your browser's cache and then resolve firewall issues. If you still have problems in loading the page please contact biomarkers@excelra.com

I have a problem not described here?

If your problem is not described here, first check to make sure that you are using one of the supported browsers. If your browser is supported and you are still experiencing a problem, please contact biomarkers@excelra.com

Why I am not able to receive email alerts I have subscribed to?

Several factors can prevent you from receiving GOBIOM email.
  • Correct Email Address: Verify that the email address of your account is correct
  • Edit or Disable Spam Filters: Edit spam or junk mail filters of your email account

If you are still experiencing the problem, please contact biomarkers@excelra.com

➤
Home
Mail
Profile
Demonstration
➤
Home
Mail
Profile
Demonstration
Loading...
NOTE: To access this application, please use Google Chrome or IE or Firefox or Safari as your browser. Please make sure that JavaScript and style sheets are enabled in the browser. This site is best viewed at a resolution of 1024x768.
Excelra Knowledge Solutions Private Limited, 6th Floor, Wing B, NSL SEZ ARENA
Plot No. 6, Survey No. 1
IDA Uppal, Hyderabad-500039

Email: biomarkers@excelra.com
Follow us on:
©GOBIOM. Terms of Use |  Privacy Policy